<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="391">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05156060</url>
  </required_header>
  <id_info>
    <org_study_id>VICC HNP 2173</org_study_id>
    <nct_id>NCT05156060</nct_id>
  </id_info>
  <brief_title>Gabapentin &amp; Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer</brief_title>
  <official_title>Phase I/II Trial of Gabapentin Plus Ketamine for Prevention and Treatment of Acute and Chronic Pain in Locally Advanced Head and Neck Cancer Patients Undergoing Primary or Adjuvant Chemoradiation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dianne Lou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to establish a safe and feasible dose for prophylactic use of a combination&#xD;
      of gabapentin and ketamine in head and neck cancer patients undergoing chemoradiation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:&#xD;
&#xD;
        -  To establish the maximum tolerated dose of ketamine in combination with gabapentin up to&#xD;
           a maximum planned dose of 40 mg three times a day.&#xD;
&#xD;
        -  To evaluate feasibility and tolerability&#xD;
&#xD;
      Exploratory:&#xD;
&#xD;
      - To assess pain, symptom burden, functionality, and quality of life&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Establish the maximum tolerated dose of ketamine in combination with gabapentin (per Common Terminology Criteria for Adverse Events Criteria 4.0)</measure>
    <time_frame>Approximately 28 days (Phase I)</time_frame>
    <description>Up to a maximum planned dose of 40 mg three times a day</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Count of participants with adverse events (Common Terminology Criteria for Adverse Events Criteria 4.0)</measure>
    <time_frame>Up to 30 post-treatment (Phase II)</time_frame>
    <description>Number of Participants With Grade 3 or 4 Adverse Events</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Head and Neck Cancer</condition>
  <condition>Locally Advanced Head and Neck Carcinoma</condition>
  <arm_group>
    <arm_group_label>Gabapentin plus Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gabapentin and Ketamine will be taken 3 times per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>Taken by mouth 3 times per day</description>
    <arm_group_label>Gabapentin plus Ketamine</arm_group_label>
    <other_name>Neurontin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Administered intranasally 3 times per day</description>
    <arm_group_label>Gabapentin plus Ketamine</arm_group_label>
    <other_name>Ketalar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven cancer of the head and neck cancer&#xD;
&#xD;
          -  Locally advanced non-metastatic disease (T3N0M0, T4N0M0, T1-4N1-3M0)&#xD;
&#xD;
          -  Planned primary or adjuvant radiation or chemoradiation therapy&#xD;
&#xD;
          -  Willing and able to provide informed consent&#xD;
&#xD;
          -  ECOG PS 0-2&#xD;
&#xD;
          -  Age â‰¥ 21 years&#xD;
&#xD;
          -  English speaking&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently on gabapentin or ketamine&#xD;
&#xD;
          -  Prior non-tolerance of gabapentin or ketamine&#xD;
&#xD;
          -  Unable to administer ketamine intranasally due to anatomical restrictions&#xD;
&#xD;
          -  History of seizure disorder&#xD;
&#xD;
          -  History of schizophrenia&#xD;
&#xD;
          -  History of increased intracranial pressure&#xD;
&#xD;
          -  Glomerular filtration rate &lt;30 mL/min/1.73 m2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dianne Lou, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vanderbilt-Ingram Service for Timely Access</last_name>
    <phone>800-811-8480</phone>
    <email>cip@vumc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Vanderbilt-Ingram Service for Timely Access</last_name>
      <phone>800-811-8480</phone>
      <email>cip@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Dianne Lou, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 30, 2021</study_first_submitted>
  <study_first_submitted_qc>November 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2021</study_first_posted>
  <last_update_submitted>November 30, 2021</last_update_submitted>
  <last_update_submitted_qc>November 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>Dianne Lou</investigator_full_name>
    <investigator_title>Sponsor Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Gabapentin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 22, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/60/NCT05156060/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

